10,742 Shares in Danaher Corporation $DHR Purchased by Mainsail Asset Management LLC

Mainsail Asset Management LLC purchased a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 10,742 shares of the conglomerate's stock, valued at approximately $2,380,000. Danaher accounts for 1.0% of Mainsail Asset Management LLC's investment portfolio, making the stock its 17th largest holding.

A number of other large investors have also recently bought and sold shares of the business. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in shares of Danaher in the third quarter valued at about $659,000. Nvwm LLC grew its holdings in shares of Danaher by 1,240.7% during the third quarter. Nvwm LLC now owns 362 shares of the conglomerate's stock worth $80,000 after buying an additional 335 shares during the last quarter. Covenant Asset Management LLC grew its holdings in shares of Danaher by 94.4% during the third quarter. Covenant Asset Management LLC now owns 5,176 shares of the conglomerate's stock worth $1,147,000 after buying an additional 2,514 shares during the last quarter. KG Capital Management purchased a new position in shares of Danaher during the third quarter worth about $622,000. Finally, Fort Washington Investment Advisors Inc. OH increased its position in Danaher by 7,466.5% in the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 669,181 shares of the conglomerate's stock valued at $148,257,000 after acquiring an additional 660,337 shares during the period. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Stock Up 0.8%

DHR stock opened at $224.65 on Thursday. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The stock has a market capitalization of $157.93 billion, a PE ratio of 39.90, a price-to-earnings-growth ratio of 2.80 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The company has a fifty day moving average of $212.92 and a 200-day moving average of $195.39.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter in the previous year, the firm earned $0.77 earnings per share. The business's quarterly revenue was up 5.5% compared to the same quarter last year. As a group, analysts expect that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher's dividend payout ratio (DPR) is presently 28.42%.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Stifel Nicolaus reduced their price objective on Danaher from $260.00 to $220.00 and set a "buy" rating for the company in a research note on Wednesday, July 22nd. Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a research report on Saturday, October 10th. Royal Bank Of Canada lifted their target price on Danaher from $215.00 to $250.00 and gave the company an "outperform" rating in a research note on Monday, October 5th. The Goldman Sachs Group boosted their target price on Danaher from $210.00 to $250.00 and gave the company a "buy" rating in a report on Monday, September 21st. Finally, TD Cowen boosted their target price on Danaher from $236.00 to $255.00 and gave the company a "buy" rating in a report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $235.41.

Danaher Company Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.